T cell lymphoma - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “T cell lymphoma - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in T cell lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
T cell lymphoma: Overview
T-cell lymphomas represent a diverse group of non-Hodgkin lymphomas of mature T-cell origin that generally are associated with unfavorable prognosis. However, recent breakthroughs have allowed a better understanding of pathogenetic mechanisms of T-cell lymphomagenesis and uncovered molecular alterations that can be assessed using new biomarker approaches and can be specifically targeted with documented improvements in outcomes. A particularly promising area in which significant progress has been made is the role of epigenetic alterations, including dysregulation of DNA methylation and histone modifications, in T-cell lymphomagenesis.
T-cell lymphomas encompass a group of heterogeneous diseases accounting for less than 10% of non-Hodgkin lymphomas. With the exception of ALK positive anaplastic large cell lymphoma, T-cell lymphomas also tend to be more clinically aggressive than their B-cell counterparts.
In spite of substantial advances in the treatment of lymphoma in general, the prognosis of patients with relapsed or treatment-refractory T-cell lymphoma remains poor, necessitating the development of novel approaches and therapies. Epigenetic dysregulation has a potential role in initiating and promoting a wide variety of malignancies and is observed in both B-cell and T-cell lymphomas.
Report Highlights
This segment of the T cell lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
T cell lymphoma Emerging Drugs
Synthetic hypericin, the active ingredient in SGX301, tends to accumulate in T-cells. Once the hypericin is in the T-cells, it can be activated by safe, visible fluorescent light. When synthetic hypericin is activated it creates oxygen radicals which subsequently cause cellular toxicity, killing the targeted T-cells. It is currently in Phase III stage of development for Cutaneous T-cell lymphoma and is being developed by Soligenix.
It is currently in Phase III stage of development for the treatment of peripheral T-cell lymphoma (PTCL) and is being developed by Solasia Pharma.
Further product details are provided in the repor
T cell lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different T cell lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
T cell lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses T cell lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging T cell lymphoma drugs.
T cell lymphoma Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “T cell lymphoma - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in T cell lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
T cell lymphoma: Overview
T-cell lymphomas represent a diverse group of non-Hodgkin lymphomas of mature T-cell origin that generally are associated with unfavorable prognosis. However, recent breakthroughs have allowed a better understanding of pathogenetic mechanisms of T-cell lymphomagenesis and uncovered molecular alterations that can be assessed using new biomarker approaches and can be specifically targeted with documented improvements in outcomes. A particularly promising area in which significant progress has been made is the role of epigenetic alterations, including dysregulation of DNA methylation and histone modifications, in T-cell lymphomagenesis.
T-cell lymphomas encompass a group of heterogeneous diseases accounting for less than 10% of non-Hodgkin lymphomas. With the exception of ALK positive anaplastic large cell lymphoma, T-cell lymphomas also tend to be more clinically aggressive than their B-cell counterparts.
In spite of substantial advances in the treatment of lymphoma in general, the prognosis of patients with relapsed or treatment-refractory T-cell lymphoma remains poor, necessitating the development of novel approaches and therapies. Epigenetic dysregulation has a potential role in initiating and promoting a wide variety of malignancies and is observed in both B-cell and T-cell lymphomas.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence T cell lymphoma R&D. The therapies under development are focused on novel approaches for T cell lymphoma.
This segment of the T cell lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
T cell lymphoma Emerging Drugs
- SGX-301: Soligenix
Synthetic hypericin, the active ingredient in SGX301, tends to accumulate in T-cells. Once the hypericin is in the T-cells, it can be activated by safe, visible fluorescent light. When synthetic hypericin is activated it creates oxygen radicals which subsequently cause cellular toxicity, killing the targeted T-cells. It is currently in Phase III stage of development for Cutaneous T-cell lymphoma and is being developed by Soligenix.
- SP-02: Solasia Pharma
It is currently in Phase III stage of development for the treatment of peripheral T-cell lymphoma (PTCL) and is being developed by Solasia Pharma.
Further product details are provided in the repor
T cell lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different T cell lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on T cell lymphoma
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
T cell lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses T cell lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging T cell lymphoma drugs.
T cell lymphoma Report Insights
- T cell lymphoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing T cell lymphoma drugs?
- How many T cell lymphoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for T cell lymphoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the T cell lymphoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for T cell lymphoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Celgene
- CSPC ZhongQi Pharmaceutical Technology
- Jazz Pharmaceuticals
- Genor Biopharma
- Eisai
- Soligenix
- Elorac
- Shanghai YingLi Pharmaceutical
- ViGenCell
- Daiichi Sankyo
- Chia Tai Tianqing Pharmaceutical Group
- BeiGene
- Kura Oncology
- Solasia Pharma
- Innovent bilogics
- Nanjing Sanhome Pharmaceutical
- Rhizen Pharmaceuticals SA
- 4SC AG
- Precision Bioscience
- Millennium Pharmaceuticals, Inc.
- Innate Pharma
- ImmuneOncia Therapeutics
- HUYA Bioscience International
- CerRx, Inc.
- Shandong New Time Pharmaceutical Co., LTD
- Verastem, Inc.
- Janssen Research & Development
- Celleron Therapeutics
- CStone Pharmaceuticals
- Viridian Therapeutics
- Hebei Senlang Biotechnology Inc.
- Galderma
- Seagen
- Bioniz Therapeutics
- Almirall
- Dizal Pharmaceuticals
- Pfizer
- Hoffmann-La Roche
- Affimed GmbH
- Sorrento Therapeutics
- Merck Sharp & Dohme
- Eli Lilly and Company
- Bayer
- Genzyme
- Portola Pharmaceuticals
- Onyx Pharmaceuticals
- AstraZeneca
- Astex Therapeutics
- Yake Biotechnology Ltd.
- Aileron Therapeutics
- Akeso Pharmaceuticals, Inc.
- Viracta
- Otsuka Pharmaceutical
- VelosBio
- Trillium Therapeutics Inc.
- Mundipharma-EDO GmbH
- TG Therapeutics, Inc.
- PersonGen BioTherapeutics (Suzhou) Co
- Sorrento Therapeutics
- Oncotartis
- Myeloid Therapeutics
- Bio-Path Holdings, Inc.
- Legend Biotech
- Immune Cell
- Genzada Pharmaceuticals
- Gracell
- CRISPR Therapeutics
- Corvus Pharmaceuticals, Inc.
- Rafael Therapeutics
- Antengene Corporation
- Viridian Therapeutics
- iCell Gene Therapeutics
- Tessa Therapeutics
- Boryung Pharmaceutical Co., Ltd
- Bristol-Myers Squibb
- Antengene Corporation
- Amgen
- ADC Therapeutics S.A.
- Legend Biotech USA Inc
- VidacPharma
- Medc Biopharma
- Scopus Biopharma
- Almirall
- Brickell Bio
- AVM Biotechnology
- Autolus
- Applied Therapeutics
- TetraLogic Pharmaceuticals
- Moleculin Biotech
- Lenalidomide
- Mitoxantrone Hydrochloride
- JZP-458
- GB226
- Denileukin diftitox
- SGX 301
- Naloxone Hydrochloride
- YY-20394
- VT-EBV-N
- Valemetostat Tosylate
- TQ-B3525
- TQ-B3101
- Tislelizumab
- Tipifarnib
- SP-02L
- SP-02
- Sintilimab
- SHC014748M
- SGN-35
- RP6530
- Resminostat
- Pembrolizumab
- PBCAR20
- Nivolumab
- MLN 9708
- Letermovir
- Lacutamab
- IPH4102
- IMC-001
- HBI-8000
- Fenretinide
- F520
- Duvelisib
- DS-3201
- Daratumumab
- CXD 101
- CS1001
- Cobomarsen
- CD7 CAR-T
- CD11301
- Brentuximab Vedotin
- BNZ132-1-40
- BNZ1
- AZD4205
- Azacytidine
- Avelumab
- Atezolizumab
- AFM13
- STI-3031
- MK-3475
- LY3039478
- Durvalumab
- Copanlisib
- Clofarabine
- Cerdulatinib (PRT062070)
- carfilzomib
- AZD5991
- ASTX660
- ALRN-6924
- AUTO4
- AK104
- Nanatinostat + Valganciclovir
- ASTX660
- ARGX-110
- VLS-101
- TTI-621
- Tinostamustine
- TGR-1202
- Temsirolimus
- Sofusa anti-PD1
- SEA-TGT
- OT-82
- MT-101
- L-Bcl-2 antisense oligonucleotide
- LB1901
- ICAR30 T cells
- GZ17-6.02
- GC027
- CTX130
- CPI-818
- CPI-613/Devimistat
- Cobomarsen
- CD4 CAR T cells
- CD30.CAR-T
- BR101801
- BMS-906024
- AZD4573
- ATG-010
- AMG 319
- ADCT-301
- LB1901
- CD7-CART
- VDA-1102
- MDC 2021
- MDC 2020
- CO-sTiRNA
- CD-7 UCART
- BNZ1
- BBI-3000
- AVM-0703
- Auto 5
- AT-104
- Lorlatinib
- CPX-351
- SHP-141
- WP1220
Introduction
Executive Summary
T cell lymphoma: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
T cell lymphoma– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
T cell lymphoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
T cell lymphoma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
SGX-301: Soligenix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
AFM13: Affimed
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
MT-101: Myeloid Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
AT-104: Applied Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
T cell lymphoma Key Companies
T cell lymphoma Key Products
T cell lymphoma- Unmet Needs
T cell lymphoma- Market Drivers and Barriers
T cell lymphoma- Future Perspectives and Conclusion
T cell lymphoma Analyst Views
T cell lymphoma Key Companies
Appendix
Executive Summary
T cell lymphoma: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
T cell lymphoma– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
T cell lymphoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
T cell lymphoma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
SGX-301: Soligenix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
AFM13: Affimed
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
MT-101: Myeloid Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
AT-104: Applied Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
T cell lymphoma Key Companies
T cell lymphoma Key Products
T cell lymphoma- Unmet Needs
T cell lymphoma- Market Drivers and Barriers
T cell lymphoma- Future Perspectives and Conclusion
T cell lymphoma Analyst Views
T cell lymphoma Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for T cell lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for T cell lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for T cell lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for T cell lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
